Condition: Alzheimer's Disease (AD) · Sponsor: Ludwig-Maximilians - University of Munich
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
This description comes directly from the study's public registry record.
Robert Perneczky, Prof.Dr.med. · +4989440055863 · PSY.Alzheimerzentrum@med.uni-muenchen.de
Lena Burow, M.Sc. · +4989440055898 · lena.burow@med.uni-muenchen.de
Always discuss trial participation with your own doctor first.
| Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums | München, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05059158